MedNet.nl: Depemokimab is a new, long-acting biological drug for the treatment of severe eosinophilic asthma. The phase III studies SWIFT-I and SWIFT-II show that this drug leads to a reduction of 58 and 48% respectively in the annual number of exacerbations.
11-09-2024 | Asthma Attack | News